A combined oral contraceptive affects mucosal SHIV susceptibility factors in a pigtail macaque model

Ostergaard, Sharon Dietz; Butler, Katherine; Ritter, Jana M.; Johnson, Ryan; Sanders, Jeanine; Powell, Nathaniel; Lathrop, George; Zaki, Sherif R.; McNicholl, Janet M.; Kersh, Ellen N.

doi:10.1111/jmp.12157

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

A combined oral contraceptive affects mucosal SHIV susceptibility factors in a pigtail macaque model

Published Date:

Dec 23 2014

Publisher's site:

http://dx.doi.org/10.1111/jmp.12157 New Site Icon

Source:

J Med Primatol. 44(2):97-107.

[PDF-1.01 MB]

Details:

Personal Authors:

Ostergaard, Sharon Dietz ; Butler, Katherine ; Ritter, Jana M. ; Johnson, Ryan ; Sanders, Jeanine ; ... More ▼

Keywords:

[+]

Pubmed ID:

25536296

Pubmed Central ID:

PMC4355188

Description:

Background

Injectable hormonal contraception may increase women’s risk of HIV acquisition, and can affect biological risk factors in animal models of HIV. We established, for the first time, a model to investigate whether combined oral contraceptives (COC) alter SHIV susceptibility in macaques.

Methods

Seven pigtail macaques were administered a monophasic levonorgestrel (LNG)/ethinyl estradiol (EE) COC at 33% or 66% of the human dose for 60 days. Menstrual cycling, vaginal epithelial thickness and other SHIV susceptibility factors were monitored for a mean of 18 weeks.

Results

Mean vaginal epithelial thicknesses was 290.8 μm at baseline and 186.2 μm during COC (p=0.0141, Mann Whitney test). Vaginal pH decreased from 8.5 during to 6.5 post- treatment (0.0176 two-tailed t-test). Measured microflora was unchanged.

Conclusions

COC caused thinning of the vaginal epithelium and vaginal pH changes, which may increase SHIV susceptibility. 0.033 mg LNG + 0.0066 mg EE appeared effective in suppressing ovulation.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

CC999999/Intramural CDC HHS/United States
Y01 AI000681-02/AI/NIAID NIH HHS/United States
Y1-A1-0681-02/PHS HHS/United States

Supporting Files:

	nihms-665469-f0005.gif	image/gif
	nihms-665469-f0005.jpg	image/jpeg
	nihms-665469.nxml	application/octet-stream
	nihms-665469-f0001.gif	image/gif
	nihms-665469-f0001.jpg	image/jpeg
	nihms-665469-f0002.gif	image/gif
	nihms-665469-f0002.jpg	image/jpeg
	nihms-665469-f0003.gif	image/gif
	nihms-665469-f0003.jpg	image/jpeg
	nihms-665469-f0004.gif	image/gif
	nihms-665469-f0004.jpg	image/jpeg

No Related Documents.

You May Also Like:

Relationship of estimated SHIV acquisition time points during the menstrual cycle and thinning of vaginal epithelial layers in pigtail macaques

Personal Author:

Kersh, Ellen N.; Ritter, Jana; Butler, Katherine; Ostergaard, Sharon Dietz; Hanson, Debra; Ellis, Shanon; Zaki, Sherif; McNicholl, Janet M.;

Published:

Dec 2015

Source:

Sex Transm Dis. 42(12):694-701.

Description:

Background : HIV acquisition in the female genital tract remains incompletely understood. Quantitative data on biological HIV risk factors, the influence of reproductive hormones, and infection risk are lacking. We evaluated vaginal epithelial thickn...

File Type:

[PDF - 314.77 KB]
A DMPA (Depot Medroxyprogesterone Acetate) Dose that Models Human Use and its Effect on Vaginal SHIV Acquisition Risk

Personal Author:

Butler, Katherine; Ritter, Jana M.; Ellis, Shanon; Morris, Monica R.; Hanson, Debra L.; McNicholl, Janet M.; Kersh, Ellen N.;

Published:

Aug 01 2016

Source:

J Acquir Immune Defic Syndr. 72(4):363-371.

Description:

Introduction : Hormonal contraception with DMPA may increase HIV acquisition risk, but observational human studies are inconclusive, and animal models can help investigate this risk. Here we test the impact of a low DMPA dose, designed to resemble hu...

File Type:

[PDF - 4.40 MB]
Macaque models of enhanced susceptibility to HIV

Personal Author:

Henning, Tara R.; McNicholl, Janet M.; Vishwanathan, Sundaram A.; Kersh, Ellen N.;

Published:

Jun 14 2015

Source:

Virol J. 12.

Description:

There are few nonhuman primate models of enhanced HIV susceptibility. Such models can improve comprehension of HIV acquisition risk factors and provide rigorous testing platforms for preclinical prevention strategies. This paper reviews past, current...

File Type:

[PDF - 672.21 KB]
Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-Intravaginal Rings Protects Macaques from Multiple SHIV Exposures

Personal Author:

Srinivasan, Priya; Moss, John A.; Gunawardana, Manjula; Churchman, Scott A.; Yang, Flora; Dinh, Chuong T.; Mitchell, James M.; Zhang, Jining; Fanter, Rob; Miller, Christine S.; Butkyavichene, Irina; McNicholl, Janet M.; Smith, Thomas J.; Baum, Marc M.; Smith, James M.;

Published:

Jun 08 2016

Source:

PLoS One. 11(6).

Description:

Topical preexposure prophylaxis (PrEP) against HIV has been marginally successful in recent clinical trials with low adherence rates being a primary factor for failure. Controlled, sustained release of antiretroviral (ARV) drugs may help overcome the...

File Type:

[PDF - 1.55 MB]
Repeated vaginal SHIV challenges in macaques receiving oral or topical Pre-Exposure Prophylaxis induce virus-specific T cell responses

Personal Author:

Tsegaye, Theodros Solomon; Butler, Katherine; Luo, Wei; Radzio, Jessica; Srinivasan, Priya; Sharma, Sunita; Aubert, Rachael D.; Hanson, Debra L.; Dobard, Charles; Garcia-Lerma, J. Gerardo; Heneine, Walid; McNicholl, Janet M.; Kersh, Ellen N.;

Published:

Aug 1 2015

Source:

J Acquir Immune Defic Syndr. 69(4):385-394.

Description:

Background : Pre-Exposure Prophylaxis (PrEP) for HIV prevention is a novel biomedical prevention method. We have previously modeled PrEP during rectal SHIV exposures in macaques and identified that SHIV-specific T cell responses were induced in the p...

File Type:

[PDF - 2.13 MB]